{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER-2+Positive+Breast+Cancer&page=10",
    "query": {
      "condition": "HER-2 Positive Breast Cancer",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 856,
    "total_pages": 86,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER-2+Positive+Breast+Cancer&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER-2+Positive+Breast+Cancer&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T13:12:07.569Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04596150",
      "title": "Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Breast Neoplasms",
        "Breast Neoplasms, Triple-Negative",
        "Breast Cancer",
        "Breast Neoplasms, Hormone Receptor Positive/HER2 Negative"
      ],
      "interventions": [
        {
          "name": "CX-2009",
          "type": "DRUG"
        },
        {
          "name": "CX-072",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytomX Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2020-12-29",
      "completion_date": "2023-06-02",
      "has_results": false,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 27,
      "location_summary": "La Jolla, California • Los Angeles, California • Santa Monica, California + 22 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04596150"
    },
    {
      "nct_id": "NCT02957968",
      "title": "Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Adenocarcinoma",
        "Estrogen Receptor- Negative Breast Cancer",
        "Estrogen Receptor-positive Breast Cancer",
        "HER2/Neu Negative",
        "Invasive Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Progesterone Receptor Positive Tumor",
        "Stage II Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Triple-negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2017-01-24",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 4,
      "location_summary": "Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more",
      "locations": [
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02957968"
    },
    {
      "nct_id": "NCT05262400",
      "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PF-07220060 + PF-07104091 combination dose escalation",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + PF-07220060 + letrozole dose expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 235,
      "start_date": "2022-03-14",
      "completion_date": "2027-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05262400"
    },
    {
      "nct_id": "NCT03630809",
      "title": "Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-positive Breast Cancer",
        "HER-2 Gene Amplification",
        "HER2 Positive Breast Carcinoma",
        "HER-2 Protein Overexpression",
        "Breast Cancer, Male",
        "Breast Cancer Female"
      ],
      "interventions": [
        {
          "name": "HER2 DC1 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2019-01-10",
      "completion_date": "2022-04-11",
      "has_results": false,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630809"
    },
    {
      "nct_id": "NCT00138125",
      "title": "Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Faslodex",
          "type": "DRUG"
        },
        {
          "name": "Herceptin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Translational Oncology Research International",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2005-04",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Redondo Beach, California • San Antonio, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00138125"
    },
    {
      "nct_id": "NCT01269346",
      "title": "Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Eribulin Mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 52,
      "start_date": "2010-12",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 26,
      "location_summary": "Denver, Colorado • Davie, Florida • Jacksonville, Florida + 22 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Davie",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01269346"
    },
    {
      "nct_id": "NCT04214288",
      "title": "A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced ER-Positive HER2-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AZD9833",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 240,
      "start_date": "2020-04-22",
      "completion_date": "2027-06-16",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Fort Myers, Florida + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214288"
    },
    {
      "nct_id": "NCT01441596",
      "title": "Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Investigator's choice of treatment",
          "type": "DRUG"
        },
        {
          "name": "afatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 121,
      "start_date": "2011-10",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2015-09-07",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 6,
      "location_summary": "Bakersfield, California • Fullerton, California • Los Angeles, California + 3 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01441596"
    },
    {
      "nct_id": "NCT07897344",
      "title": "Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Hormone Receptor Positive / HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dietary Protein Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Josephine Connolly-Schoonen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2026-11-03",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07897344"
    },
    {
      "nct_id": "NCT02088684",
      "title": "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        },
        {
          "name": "BYL719",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "BKM120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 70,
      "start_date": "2014-05-19",
      "completion_date": "2018-04-17",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-11-15T13:12:07.569Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02088684"
    }
  ]
}